论文部分内容阅读
目的观察急性冠脉综合征(ACS)应用阿司匹林和辛伐他汀对其高敏性C-反应蛋白(hs-CRP)及预后的影响。方法将血浆高敏性C-反应蛋白浓度增高的急性冠脉综合征(ACS)患者分成三组:A组为阿司匹林+辛伐他汀组,56例。B组为辛伐他汀组,56例。C组为阿司匹林组,55例。观察治疗后7天及出院随访一年,血浆中高敏性C-反应蛋白(hs-CRP)变化及主要心脑血管事件的发生情况。结果三组患者治疗后7天血浆中高敏性C-反应蛋白(hs-CRP)均有下降,但A组(阿司匹林+辛伐他汀组)较B组(辛伐他汀组)及C组(阿司匹林组)下降幅度大(P均<0.05)差异有显著性,主要心脑血管事件发生率A组(阿司匹林+辛伐他汀组)较B组(辛伐他汀组)及C组(阿司匹林组)低(P均<0.05)差异有显著性。结论阿司匹林联合辛伐他汀应用于血浆高敏性C-反应蛋白(hs-CRP)浓度增高的急性冠脉综合征(ACS)患者,能更有效地降低血浆高敏性C-反应蛋白(hs-CRP)浓度及主要心脑血管事件发生率,且不良反应发生率低,值得临床推广应用。
Objective To observe the effect of aspirin and simvastatin on the hypersensitivity C-reactive protein (hs-CRP) and prognosis in patients with acute coronary syndrome (ACS). Methods Acute coronary syndromes (ACS) patients with elevated plasma concentrations of hypersensitivity C-reactive protein were divided into three groups: A group was aspirin + simvastatin group, 56 cases. Group B was simvastatin group, 56 cases. C group aspirin group, 55 cases. The changes of plasma high-sensitivity C-reactive protein (hs-CRP) and the occurrence of major cardiovascular events at 7 days after treatment and one year after discharge from hospital were observed. Results The levels of plasma hs-CRP decreased in all three groups 7 days after treatment, but were lower in group A (aspirin + simvastatin group) than in group B (simvastatin group) and group C (aspirin (P <0.05). The incidence of major cardiovascular events was lower in group A (aspirin + simvastatin group) than group B (simvastatin group) and group C (aspirin group) (P <0.05), the difference was significant. Conclusions The combination of aspirin and simvastatin in patients with acute coronary syndrome (ACS) with elevated plasma concentrations of hs-CRP can decrease plasma hs-CRP levels more effectively. Concentration and the incidence of major cardiovascular events, and the incidence of adverse reactions is low, worthy of clinical application.